Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Spatz

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 17, 2021
Molecular immuno-imaging improves tumor detection in head and neck cancerJing-Hui Li, Reza Forghani, Lionel Bure, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaRahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 27, 2020
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selectionPeter C Black, Nimira S Alimohamed, David Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic MelanomaWim H J Kruit, Stefan Suciu, Brigitte Dreno, et al.
Molecular Cancer Therapeutics|June 28, 2019
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical OutcomesMathilde Couëtoux du Tertre, Maud Marques, Lise Tremblay, et al.
Cancer Treatment and Research Communications|March 23, 2023
Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centreMark Sorin, Sophie Camilleri-Broët, Emilie Pichette, et al.
Cancers|August 7, 2021
Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning ModelsXiaoyang Liu, Farhad Maleki, Nikesh Muthukrishnan, et al.
Pigment Cell & Melanoma Research|September 30, 2010
Genetic and morphologic features for melanoma classificationSigrid M C Broekaert, Ritu Roy, Ichiro Okamoto, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanomaAlexander M M Eggermont, Stefan Suciu, Alessandro Testori, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 17, 2021
Molecular immuno-imaging improves tumor detection in head and neck cancerJing-Hui Li, Reza Forghani, Lionel Bure, et al.
Journal for Immunotherapy of Cancer|November 22, 2017
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanomaRahima Jamal, Réjean Lapointe, Eftihia Cocolakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2013
Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor > 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trialAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 27, 2020
Optimizing management of advanced urothelial carcinoma: A review of emerging therapies and biomarker-driven patient selectionPeter C Black, Nimira S Alimohamed, David Berman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2013
Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic MelanomaWim H J Kruit, Stefan Suciu, Brigitte Dreno, et al.
Molecular Cancer Therapeutics|June 28, 2019
Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical OutcomesMathilde Couëtoux du Tertre, Maud Marques, Lise Tremblay, et al.
Cancer Treatment and Research Communications|March 23, 2023
Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centreMark Sorin, Sophie Camilleri-Broët, Emilie Pichette, et al.
Cancers|August 7, 2021
Site-Specific Variation in Radiomic Features of Head and Neck Squamous Cell Carcinoma and Its Impact on Machine Learning ModelsXiaoyang Liu, Farhad Maleki, Nikesh Muthukrishnan, et al.
Pigment Cell & Melanoma Research|September 30, 2010
Genetic and morphologic features for melanoma classificationSigrid M C Broekaert, Ritu Roy, Ichiro Okamoto, et al.
Pageof 8